Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Fineline Cube Apr 28, 2026
Company Deals

MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil

Fineline Cube Dec 20, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...

Company Deals

Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB

Fineline Cube Dec 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...

Company Deals

BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal

Fineline Cube Dec 20, 2024

Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...

Company Deals

Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform

Fineline Cube Dec 20, 2024

China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...

Company Digital

Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights

Fineline Cube Dec 20, 2024

Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...

Company Deals

HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies

Fineline Cube Dec 20, 2024

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has...

Company Drug

Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Dec 20, 2024

China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...

Company Drug

Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment

Fineline Cube Dec 20, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with...

Company Deals

HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases

Fineline Cube Dec 20, 2024

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine

Fineline Cube Dec 20, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...

Company Deals

Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment

Fineline Cube Dec 20, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial

Fineline Cube Dec 20, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...

Company Drug

MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review

Fineline Cube Dec 19, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company Deals

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases

Fineline Cube Dec 19, 2024

US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...

Company Deals

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development

Fineline Cube Dec 19, 2024

Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids...

Company Deals

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets

Fineline Cube Dec 19, 2024

US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...

Company Medical Device

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit

Fineline Cube Dec 19, 2024

China-based DaAn Gene Co., Ltd, (SHE: 002030) affiliated with Sun Yat-sen University, has announced that...

Company Drug

MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer

Fineline Cube Dec 19, 2024

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...

Company Deals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

Fineline Cube Dec 19, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...

Company Drug

Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults

Fineline Cube Dec 19, 2024

China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...

Posts pagination

1 … 234 235 236 … 658

Recent updates

  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
  • Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”
  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Company Drug

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Company Drug

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.